PRostate Cancer Enhanced Diagnosis by Calibration Technology

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorGold Standard Phantoms

About this trial

The CARE® Phantom system is a medical device system that is being developed has been designed to enable the quantitative measurement of the apparent diffusion coefficient (ADC) in the prostate of patients undergoing a multi-parametric MRI (mpMRI) scan to detect prostate cancer. The final device system will comprise three elements: a calibration mat containing phantoms and embedded monitoring software, a docking station to transfer data from the phantoms, and software as a medical device (SaMD) for calibrating the resulting mpMRI images.

In this clinical trial, patients will undergo MRI scanning in different scanners using the GSP Phantoms to provide mpMRI images and phantom data for subsequent in silico analysis. The captured images and data will be used to further develop and calibrate the GSP prototype SaMD part of the medical device system, and to establish the degree of optimised reproducibility that can be achieved.

Eligibility criteria

Qualifiers

Men aged 18 years and older undergoing investigations for PCa.

Standard of Care MRI conducted.

One or more lesions with a Likert score of 3 or above identified on clinical reports.

Planned targeted biopsy within 6 months from the date of clinical care MRI.

Disqualifiers

Prostate specific antigen (PSA) level > 20ng/ml within 6 months

Previous diagnosis of prostate cancer

Ongoing hormone treatment within 3 months prior to MRI, excluding antiandrogens or 5-alpha reductase inhibitors

Contraindication to MRI scan

Trial design

Treatments tested in this trial

  • MRI

Treatment groups

66 Participants
are divided into 1 treatment group

Sponsors and collaborators

Gold Standard Phantoms

Lead sponsor

Bioxydyn Ltd, Manchester

Collaborator

National Cancer Imaging Translational Accelerator

Collaborator

University College London Hospitals

Collaborator

National Hospital of Neurology and Neurosurgery, Queens Square, London, UK

Collaborator